NYMC Faculty Publications
Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration
Author Type(s)
Faculty
DOI
10.3928/23258160-20250304-02
Journal Title
Ophthalmic Surgery Lasers and Imaging Retina
First Page
468
Last Page
477
Document Type
Article
Publication Date
8-1-2025
Department
Ophthalmology
Disciplines
Medicine and Health Sciences
Abstract
BACKGROUND AND OBJECTIVE: This study assessed treatment patterns and early outcomes among patients with neovascular age-related macular degeneration (nAMD) initiating faricimab in routine clinical practice in the United States. PATIENTS AND METHODS: FARETINA-AMD is a retrospective study among patients with nAMD initiating faricimab from February 2022 to June 2023 identified from the US IRIS® Registry. RESULTS: Included were 21,508 patients previously treated with anti-vascular endothelial growth factor (anti-VEGF) (25,784 eyes) and 1,836 treatment-naïve patients (1,982 eyes) with nAMD. Among previously treated eyes, visual acuity remained stable with faricimab. In treatment-naïve eyes, mean ± SD visual acuity improved from 56.7 ± 24.1 letters at index to 61.4 ± 22.3 after faricimab injection 4 (P < 0.01). Mean ± SD central subfield thickness improved from 315.2 ± 80.0 (index) to 264.9 ± 60.1 μm (injection 4) in treatment-naïve eyes and 296.2 ± 95.5 to 273.0 ± 81.4 μm in previously treated eyes (both P < 0.01). CONCLUSIONS: Among patients with nAMD receiving faricimab, visual acuity improved in treatment-naïve eyes, and both previously treated and treatment-na-ïve eyes experienced anatomical improvement.
Recommended Citation
Ali, F., Tabano, D., Borkar, D., Leng, T., Garmo, V., Ahmed, A., Myers, R., Shaia, J., Barteselli, G., & Singh, R. (2025). Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 56 (8), 468-477. https://doi.org/10.3928/23258160-20250304-02
